Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with clinically definite Multiple Sclerosis (MS, all MS subtypes);~2. Age 18 years or older;~3. Presence of chronic, problematic fatigue that, in the opinion of the patient, has interfered with their daily activities for ≥ 3 months;~4. Average Fatigue Severity Scale (FSS) score greater or equal to 4 at screening.~Exclusion Criteria:~1. Current shift work sleep disorder, or narcolepsy diagnosed with polysomnography and multiple sleep latency test~2. History of MS relapse within the last 30 days prior to screening (participants will be considered eligible after the 30-day window);~3. Current stimulant or wake-promoting agent use (such as amantadine, modafinil, methylphenidate, or amphetamine) within 30 days of screening;~4. Pregnancy or breastfeeding;~5. Reliance on hormonal contraception AND concomitant unwillingness to use alternative non-hormonal means of birth control (spermicide or condoms) during the course of the study;~6. Current suicidal ideation (SI) with intent or plan;~7. Known hypersensitivity to modafinil or armodafinil or its inactive ingredients;~8. History of the following cardiovascular conditions: recent myocardial infarction (last 6 months prior to screening), unstable angina, left ventricular hypertrophy, mitral valve prolapse, NYHA class III or IV congestive heart failure;~9. History of prescription or illicit stimulant abuse (such as cocaine, amphetamine, methamphetamine);~10. Any other medical, neurological, or psychiatric condition that, in the opinion of the investigators, could affect participant safety or eligibility.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Therapy (Type: ACTIVE_COMPARATOR): 8 weekly telephone-based sessions and 2 booster sessions
- Modafinil (Type: ACTIVE_COMPARATOR): 50-400 mg per day (oral)
- Cognitive Behavioral Therapy + Modafinil (Type: ACTIVE_COMPARATOR): Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).